VEGFA and retinal vascular disorder: By simultaneously targeting VEGF and Ang-2—two distinct signaling pathways implicated in retinal vascular disorders—faricimab not only effectively suppresses VEGF-mediated neovascularization but also enhances vascular stability and mitigates inflammation through Ang-2 inhibition (18, 90).